Successful Treatment of Hepatitis C, Genotype 3, Treatment Failure (Sofosbuvir/Daclatasvir) with Sofosbuvir/Velpatasvir in Decompensated Cirrhosis Complicated by Renal Insufficiency [PDF]
, 2019 Marco Distefano +5 more
openalex +1 more source
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
, 2022 Xiaodan Ren +5 more
openalex +1 more source
Genotype 1 and 3 Response to Velpatasvir and Sofosbuvir in Chronic Hepatitis C in the Kashmiri Population: An Observational Study [PDF]
, 2019 Suresh Gorka +9 more
openalex +1 more source
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection [PDF]
, 2021 Gail Matthews +65 more
openalex +1 more source
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]
, 2015 BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Afdhal, Nezam +34 more
core +1 more source
5PSQ-032 Successful treatment of chronic hepatitis C infection with crushed sofosbuvir/velpatasvir [PDF]
, 2020 A Puebla Villaescusa +3 more
openalex +1 more source
Quantification of Sofosbuvir and Velpatasvir in Human Plasma using LCMS/MS Technique -Application to Pharmacokinetic Study [PDF]
, 2019 Kishore Konam, Somasekhar Reddy
openalex +1 more source
Simultaneous Estimation of Sofosbuvir and Velpatasvir Tablets by RP- HPLC Method
, 2018 V Sreehitha +5 more
openalex +1 more source
IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis [PDF]
, 2019 Sergio Borgia +14 more
openalex +1 more source